论文部分内容阅读
前期多中心临床研究显示,26S蛋白酶体抑制剂硼替佐米(bortezom ib/PS-341)单药仅可使约30%的复发或难治性多发性骨髓瘤(MM)患者获得部分缓解(PR)或完全缓解(CR)[1]。如何优化硼替佐米用法,以更大限度地发挥其协同抗瘤作用是目前临床研究的热点[2]。体外实验证实,硼替佐米与阿霉
Previous multi-center clinical studies showed that the 26S proteasome inhibitor bortezom ib / PS-341 alone regained partial remission (PR) in approximately 30% of patients with relapsed or refractory multiple myeloma (MM) ) Or complete remission (CR) [1]. How to optimize the usage of bortezomib in order to exert its synergistic antitumor effect to a greater extent is a hot issue in clinical research [2]. In vitro experiments confirmed that bortezomib and Adriamycin